Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Details)

v2.4.0.8
Composition of Certain Financial Statement Captions (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Accounts receivable, net:    
Accounts receivable $ 23,135 $ 21,636
Less: allowance for doubtful accounts (908) (474)
Accounts receivable, net 22,227 [1] 21,162 [1]
Inventories, net:    
Finished products 15,169 17,963
Work in-process 1,253 688
Raw materials 4,721 4,923
Less: inventory reserve (1,365) (1,313)
Inventory, net 19,778 [1] 22,261 [1]
Intangible assets, net:    
Technologies 52,796 52,810
Customer relationships 22,839 23,088
Product registrations 9,690 9,637
Tradenames 3,683 3,746
Covenants not to compete 8,660 8,662
Other 1,180 367
Less: accumulated amortization (19,073) (14,072)
Intangible assets, net 79,775 84,238
Accrued expenses:    
Income taxes payable 2,421 1,614
Deferred revenue 3,903 1,518
Clinical trials 315 50
Professional fees 933 675
Employee benefits 3,972 3,319
Deferred acquisition payments, net of discount 5,432 6,172
Contingent consideration 5,298 5,126
Interest payable related to the Notes 2,275 0
Other 6,496 6,182
Accrued expenses 31,045 24,656
Other long-term liabilities:    
Deferred acquisition payments, net of discount 3,983 3,931
Mortgages and other debts payable 3,636 5,150
Deferred tax liabilities 7,185 9,777
Other, including deferred revenue 2,191 380
Other long-term liabilities 80,603 [1] 34,168 [1]
Cytochroma [Member]
   
Other long-term liabilities:    
Contingent consideration 49,784 0
Farmadiet [Member]
   
Other long-term liabilities:    
Contingent consideration 529 532
OPKO Diagnostics [Member]
   
Other long-term liabilities:    
Contingent consideration 12,746 11,310
FineTech [Member]
   
Other long-term liabilities:    
Contingent consideration 0 2,578
CURNA [Member]
   
Other long-term liabilities:    
Contingent consideration $ 549 $ 510
[1] As of June 30, 2013 and December 31, 2012, total assets include $6.0 million and $5.6 million, respectively, and total liabilities include $7.8 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities are those as to which there is no recourse against us. Refer to Note 5.